Learn how Syngene screened 50,000 compounds using high throughput screening against two different transcription factors for accelerated drug discovery.
SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Learn how Syngene screened 50,000 compounds using high throughput screening against two different transcription factors for accelerated drug discovery.
Nanofiltration is a highly effective viral clearance method in mAb manufacturing, primarily based on size exclusion. An essential part of validating the efficacy of the nanofiltration step are virus spiking studies to ensure the nanofiltration process can reliably remove viruses and meet regulatory requirements for product safety.
A major pharmaceutical company was facing challenges in the nanofiltration step of their mAb production process. During virus spiking at 1% – 0.5% of the load volume, they encountered reduced filtration efficiency and flux decay. These issues affected the overall performance of the nanofiltration step, including increasing operational costs due to the need for frequent filter changes.
The pharma company decided to partner with Syngene to address these problems. Their goal was to improve the efficiency of the nanofiltration process in order to achieve viral clearance and reduce operational costs
Our team approached the problem by focusing on optimizing the nanofiltration process. The solution involved a multi-step methodology.
After implementing our solution, the client successfully achieved the desired target throughput with flux decay levels at under 40%. The virus aggregates were effectively controlled, resulting in a more efficient and cost-effective nanofiltration process. The optimized process enabled the client to operate at higher flow rates, while maintaining effective virus clearance throughout the process. The new process also required fewer filter changes, significantly reducing overall costs.
The client is considering further collaboration with Syngene to explore additional optimizations and innovations in their manufacturing processes. Our expertise continues to be a key driver in advancing the client’s production capabilities and ensuring continued success in drug manufacturing.
Our ongoing capability and capacity expansion in biologics have established Syngene as one of the largest CRDMOs in India. As a trusted biologics partner, we have delivered 100 commercial batches in the last two years. Our track record of over 250 GMP batches, 150+ projects, and support for over 25 INDs across biologics modalities is a testament to our expertise
To know more about our Viral Testing and Clearance services, contact our experts
© 2024. Syngene International Limited